

\Date: Fri, 2 Apr 1999 17:00:34 -0500 (EDT)
Date: Fri, 2 Apr 1999 17:00:35 -0500 (EDT)
From: "Account DRUGINFO." <DRUGINFO@cder.fda.gov>
Subject: FWD: FDA Comments
To: Fred Richman <RICHMANF@cder.fda.gov>
Message-id: <B1906IVY3NBSE*/R=A1/R=DONALD/U=DRUGINFO/@MHS>
MIME-version: 1.0
Content-type: MULTIPART/MIXED; BOUNDARY="Boundary_(ID_211Le92hwwKANZUTUcW54A)"
Delivery-date: Fri, 2 Apr 1999 17:00:00 -0500 (EDT)
Posting-date: Fri, 2 Apr 1999 17:00:35 -0500 (EDT)
Importance: normal
Priority: normal
Sensitivity: Company-Confidential
Al-type: MAIL

--Boundary_(ID_211Le92hwwKANZUTUcW54A)
Content-type: TEXT/PLAIN; CHARSET=US-ASCII

Compounding

Name: Pamela Anderegg

E-Mail: pda@Relex.com

Comments: > Will this affect your ability to compound and ship
special prescriptions, such as gluten free ones,
to out-of-state customers?

>

> Concerned in Baltimore,
> Bobbi

Yes. I need grass roots objections to this proposal. William
Milazzo
R.Ph.

We are in need of gluten free prescriptions.
Please keep this in mind when you make laws or rulings.
Thank you.
Pamela Anderegg
Auburn, NY

--Boundary_(ID_211Le92hwwKANZUTUcW54A)
Content-type: MESSAGE/RFC822

Date: Wed, 24 Mar 1999 16:15:59 -0500 (EDT)
Date: Wed, 24 Mar 1999 16:16:01 -0500 (EDT)
From: Account CDEREXSEC FAX t- <CDEREXSEC@cder.fda.gov>
Subject: FWD: FDA Comments
To: "Account DRUGINFO." <DRUGINFO@cder.fda.gov>
Message-id: <B1590IVP3I1AN*/R=A1/R=DONALD/U=CDEREXSEC/@MHS>

98N-1265

C950